8-oxo-N-phenylnonanamide | 1445107-27-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 8-oxo-N-phenylnonanamide
• CAS: 1445107-27-6
• 化学式: C₁₅H₂₁NO₂
• 分子量: 247.337
• InChiKey: UDCLSCHIWFFWEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  7-苯基氨基甲酰基庚酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 43.0h， 生成 8-oxo-N-phenylnonanamide
  参考文献：
  名称：

  各种锌结合基团对组蛋白脱乙酰基酶1-11的抑制作用

  摘要：

  组蛋白脱乙酰基酶（HDAC）具有裂解多种蛋白质中ε - N-乙酰化赖氨酸残基的乙酰基的能力。鉴于人类细胞包含成千上万个不同的乙酰化赖氨酸残基，HDACS可以调节多种过程，包括某些与癌症和神经退行性疾病等疾病有关的过程。在这里，我们报告了一系列化合物的合成和体外生化分析，包括已知的抑制剂以及新颖的化学型，这些化合物结合了新的锌结合域。通过评估针对所有11种重组人HDAC的化合物集合，我们发现三氟甲基酮官能团可有效抑制Zn 2+的所有四个亚类依赖的HDAC。用两种不同的支架观察到有效的抑制作用，证明了三氟甲基酮部分作为锌结合基序的效率。有趣的是，我们还将硅烷二醇确定为锌结合基团，对于将来开发非I-异羟肟酸酯I类和IIb B类HDAC抑制剂具有潜力。

  DOI：

  10.1002/cmdc.201300433

文献信息

• Method of treating cancers with SAHA and pemetrexed
  申请人：Pluda James

  公开号：US20070117815A1

  公开（公告）日：2007-05-24

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

  本发明涉及一种治疗需要的受试者癌症的方法，通过向需要的受试者施用一定量的组蛋白去乙酰化酶（HDAC）抑制剂或其药用可接受的盐或水合物的第一量，以及一定量的抗癌药物。HDAC抑制剂和抗癌药物可以被施用以包含治疗有效量。在各种方面，HDAC抑制剂和抗癌药物的效果可能是相加的或协同的。
• Polymorphs of suberoylanilide hydroxamic acid
  申请人：Miller Thomas A.

  公开号：US20080194692A1

  公开（公告）日：2008-08-14

  The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.

  本发明提供了通过给予含有强效HDAC抑制剂的药物组合物来选择性诱导肿瘤细胞的终端分化、细胞生长停滞和/或凋亡，并/或抑制组蛋白去乙酰化酶（HDAC）的方法。本发明中药物组合物中活性化合物的口服生物利用度出乎意料地高。此外，该药物组合物意外地产生了活性化合物的高、治疗有效的血液水平，持续时间较长。本发明还提供了一种安全的、每日剂量的服用方案，易于遵循，并在体内产生治疗有效量的HDAC抑制剂。本发明还提供了一种SAHA的Form I多晶形态，其具有独特的X射线衍射图案和差示扫描量热法（DSC）谱图，以及独特的晶体结构。
• CHEMICAL COMPOUNDS
  申请人：Axten Jeffrey Michael

  公开号：US20120077828A1

  公开（公告）日：2012-03-29

  The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R 1 , R 2 , and R 3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的吲哚啉衍生物。具体而言，本发明涉及按式I所示的化合物：其中R1、R2和R3在此定义。本发明的化合物是PERK的抑制剂，可用于治疗癌症、眼部疾病和与激活的未折叠蛋白质应答途径相关的疾病，如阿尔茨海默病、中风、1型糖尿病帕金森病、亨廷顿病、肌萎缩性侧索硬化、心肌梗死、心血管疾病、动脉硬化和心律失常，更具体地，乳腺癌、结肠癌、胰腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物抑制PERK活性和治疗相关疾病的方法。
• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：Johnson Neil W.

  公开号：US20140018393A1

  公开（公告）日：2014-01-16

  This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

  本发明涉及使用环丙胺衍生物来调节，特别是抑制赖氨酸特异性去甲基化酶1（LSD1）的活性。适当地，本发明涉及使用环丙胺衍生物来治疗癌症。
• Methods of using SAHA and Erlotinib for treating cancer
  申请人：Bunn Paul

  公开号：US20070197568A1

  公开（公告）日：2007-08-23

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.